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Suppression ofgastric acid secretion is widely used and logical forthe treatment
of acid-related diseases. Healing of duodenal ulcer, gastric ulcer and gastroe-
sophageal reflux disease is correlated significantly with the degree and the dura-
tion of suppression of intragastric acidity over 24 hours and with the length of
the treatment. To date, proton pump inhibitors are the most effective agents
among the currently available antisecretory drugs in offering the highest heal-
ing rate and fastest resolution of symptoms. Combinations of an antisecretory
drug with one or more antimicrobial agents accelerate healing of peptic ulcers.
INTRODUCTION
Gastric acid is considered an important physiological factor in maintaining normal
upper gastrointestinal (GI)b function. Gastric acid activates pepsin, modulates gastrin
release, has a bactericidal action and facilitates calcium and iron absorption.
Abnormalities of acid secretion are associated with a number of upper GI diseases. In
patients with duodenal ulcer (DU), acid hypersecretion is seen commonly, and the concept
ofself-digestion by gastricjuice became fashionable with the dictum ofSchwarz "No acid
- no ulcer." Gastroesophageal reflux disease (GERD), gastric ulcer (GU) and ulceration
in hypersecretory conditions such as Zollinger-Ellison syndrome are also considered to
result from an imbalance between intraluminal acid and mucosal defensive factors.
Moreover, many patients with these conditions benefitfromantisecretory therapy, and this
supports the important role ofgastric acid in the pathogenesis ofthese diseases.
Since the isolation ofHelicobacterpylori more than a decade ago [1], our perception
ofthe pathogenesis ofgastroduodenal ulceration has been changed dramatically. To most,
the evidence is now conclusive that this microorganism causes over 90 percent ofduode-
nal ulcer and about 70 percent of gastric ulcer [2]. Many studies have shown that both
healthy volunteers and duodenal ulcer patients with H. Pylori infection have increased
basal and maximum pentagastrin- and gastrin-releasing, peptide-stimulated acid secretion
[3-5] and pepsin output [3]. Furthermore, eradication ofH. pylori infection results in nor-
malization of these abnormalities in acid secretion [3-5] and dramatically reduced DU
recurrence [6]. Thus, eradication ofH. pylori infection has important implications for the
concept ofcontrolling gastric acid secretion in H. pylori positive ulcer patients [7].
The healing of GERD, DU and GU by antisecretory drugs is each highly correlated
with the control ofgastric acid secretion [8-10]. The goals of treatment for these diseases
are to relieve the symptoms, to heal the established lesions and to prevent the development
of recurrence and complications. Many clinical trials have been carried out to achieve
these goals; however, the results vary between drugs and regimens. This paper will focus
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on the relationship ofpH to ulceration and symptoms and to the control ofintragastric pH
and healing rate and symptom relief in patients with GERD and peptic ulcer diseases.
PHYSIOLOGY OF SECRETION OF GASTRIC ACID
Gastric acid is secreted from the parietal cells and pepsinogen from the chiefcells in
the gastric fundus. Under the activation of gastric acid, pepsinogens are transformed into
the active enzyme, which initiates protein digestion. The peptic activity in gastric juice is
pH-dependent with maximal activity at pH 1.5 to 2 [11]. When the pH is increased above
3, the activity of pepsin decreases markedly, and this correlates well with experimental
esophagitis [11]. Under normal circumstances, secretion of gastric acid has a circadian
rhythm, with a rise in gastric acid secretion during the day and decreasing secretion dur-
ing the night [12]. Twenty-four hour intragastric pH monitoring studies show that inges-
tion of a meal has a major impact on intragastric acidity and results in an immediate rise
ofpH due to buffering by the meal. Subsequently a gradual fall ofintragastric pH is seen
as the neutralizing capacity of the meal is exceeded [13]. Thus the peak times of intra-
gastric acidity occur when basal acid secretion is unaffected by meals in the postprandial
period and during the night.
The regulation of acid secretion is complex. Classical physiological studies have
shown that at least three types of receptor on the parietal cell are involved in the regula-
tion of acid secretion. Receptors are stimulated by acetylcholine through the neurocrine
pathway (M3 receptors), by gastrin through a hormonal pathway (gastrin receptors) and
by histamine through a paracrine pathway (histamine receptors) [14]. The relevance and
importance of post-receptor interactions between these receptors have been discussed for
many years [15]; however, the H+/K+-ATPase or proton pump is recognized as the final
common pathway to acid secretion for these three receptors [15].
ACID IN GASTROESOPHAGEAL REFLUX DISEASE
Gastroesophageal reflux disease is considered to be primarily a motility disorder
characterized by abnormally frequent transient relaxations of the lower esophageal
sphincter and loss oflower esophageal sphincter tone in the basal state [16]. Both ofthese
abnormalities facilitate reflux of acidic gastric contents into the lower esophagus.
Furthermore, clearance ofthe acidic refluxate from the esophagus is impaired in about 50
percent ofpatients with GERD [17]. This results in prolonged exposure of the mucosa of
the lower esophagus to the damaging effects of acidic gastric contents. In some patients,
delayed gastric emptying [18] and abnormal duodenogastric reflux [19] may make the
refluxate, containing duodenal contents, more irritant to the esophageal squamous
mucosa.
Gastric acid and Symptoms in GERD
Despite the evidence ofdysmotility, gastric acid is considered ofcentral importance to
the initiation and continuation of the esophageal mucosal damage and the development of
symptoms in patients with GERD. The question of acid hypersecretion has been examined
by Hirschowitz, who compared 155 patients with endoscopically defined esophagitis and
508 controls without esophagitis [20]. There was no significant difference in basal or max-
imal gastric acid secretion between the groups, and the severity ofesophagitis was notrelat-
ed to any parameters ofacid secretion. However, there are a number ofstudies showing that
the severity and frequency ofsymptoms including heartburn, regurgitation and pain signif-
icantly correlate with the duration of gastroesophageal reflux, the degree of esophageal
exposure to acid, and thepH ofthe refluxate [21, 22]. The longer the duration ofacid expo-
sure, the more severe were the symptoms. Furthermore, it has been shown that the
esophageal mucosa is sensitive to acid both in humans [22] and in an animal model [11].
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Using intraesophageal perfusion ofhydrochloric acid (HCl) at different pH values, Smith et
al. evaluated the sensitivity of the esophageal mucosa in 25 symptomatic patients with
GERD [22]. All subjects experienced pain when the perfusate had a pH between 1 and 1.5.
Eighty percent had pain at pH 2.0, and halfexperienced pain with the pH between 2.5 and
6.
Importance ofPepsin in GERD
Pepsin is one of the major components of the refluxate in patients with GERD [23].
Active pepsin can be found in almost all reflux episodes detected by pH monitoring. The
concentration of pepsin in the refluxate correlates significantly with severe esophagitis,
particularly at night [23]. Symptoms, especially dysphagia, also have a significant corre-
lation with pepsin concentration [23]. This evidence confirms early experimental obser-
vations that pepsin can cause esophageal mucosal damage in an acidic medium [11, 24].
However, since the peptic activity is pH dependent [11], it is possible, pharmacologically,
to reduce the damaging effect of pepsin on the esophageal mucosa by increasing the pH
of the refluxate above 4 to inhibit the activity ofpepsin. The less effective control of the
diurnal intragastric pH during the treatment with H2RA still allows pepsin to have prote-
olytic activity, while the mean pH achieved with proton pump inhibitors (PPIs) is high
enough to virtually abolish peptic activity [25]. Thus, acid suppression is appropriate for
patients with GERD to minimize the injurious effect ofboth acid and pepsin.
Bile Acids
The damaging effect ofbile acids on the esophagus and the mechanism ofpathogen-
esis is not well documented. Bile may have a role in the development of so-called alka-
line reflux esophagitis in achlorhydric patients [26], orin a subgroup ofpatients with com-
plicated GERD [27, 28], or in patients with a history ofgastric surgery [29]. Recent stud-
ies have shown that esophageal exposure to bile acids is not common in normal subjects,
while patients with erosive esophagitis and Barrett's metaplasia have increased
esophageal exposure to a refluxate containing duodenal juice [30, 31]. Simultaneous 24-
hr pH measurement and bile monitoring ofthe distal esophagus found a close association
between duodeno-gastro-oesophageal reflux and the total proportion of time the pH was
less than 4 (p < .001) but not greater than 7. This suggests that acid reflux is the primary
factor in the development of Barrett's metaplasia and that bile reflux may have a syner-
gistic role in the progression of the severity of the esophagitis [28].
RATIONALE OF ACID SUPPRESSION IN THE MANAGEMENT OF GERD
Despite abnormal motor function in the loweresophagus ofpatients with GERD, gas-
tric acid is deemed essential to the development ofsymptoms and mucosal damage. Intra-
esophageal acid perfusion, as with the Bernstein test, has been used for the diagnosis of
patients with symptoms suggestive of GERD, and 24-hr intra-esophageal pH monitoring
is widely accepted as a standard test to detect reflux of acidic gastric contents into the
esophagus [32]. The time course ofreflux is different between patients with mild erosive
esophagitis or normal endoscopic appearances and patients with more severe erosive
esophagitis. Daytime reflux alone, which is often closely related to symptoms, is seen
more commonly in mild cases, while patients with more severe grades ofesophagitis have
frequent nocturnal reflux and long-lasting acid exposure [21, 33-36], which also may be
associated with the development ofcomplications ofGERD [33].
However, data on the relationship between acid secretion, acid exposure time and the
severity of esophagitis and symptoms have been conflicting [21, 37-39]. One large study
from Sweden compared 24-hrpHmonitoring from 190symptomatic patients and 50normal
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controls [21]. Reflux symptoms correlated well withthe duration ofacidexposure (seeTable
1).
A threshold ofpH 4.0 has been suggested by most investigators as the optimal pH to
differentiate physiological and pathological reflux [22, 32, 40]. Ifthe pH is above 4, only
a small proportion ofpatients experience esophageal pain during the Bernstein test [22].
This threshold has a maximum sensitivity of93.3 percent and specificity of 92.9 percent
[40]. Thus, ifthe intraesophageal pH ofthe refluxate can be maintained at or above 4 over
the 24-hr period, a majority ofpatients will remain symptom free and undergo healing of
esophagitis [9]. More recently, we have suggested a new analysis of 24-hr pH recording
as a clinical predictor ofesophageal mucosal damage and endoscopic grade ofesophagi-
tis [41]. We took data from 33 continuous 24-hr esophageal pH recordings performed in
patients with varying grades ofesophagitis, and calculated the area under the curve to rep-
resent total hydrogen activity (H+) and hence acid exposure. A significant difference was
seen between AUC for H+ activity and all grades of esophagitis (see Table 2). This pre-
dictor might prove to be more accurate than the broad criteria of damage associated with
the pH 4 threshold and four percent acid exposure time and could be used as a predictive
model ofesophageal mucosal damage and endoscopic grades ofesophagitis.
CLINICAL TRIALS OFANTISECRETORY DRUGS IN GERD
Many studies with conventional doses of cimetidine and ranitidine have not shown
much superiority over placebo in relieving symptoms and healing esophageal mucosal
lesions in patients with GERD (for review see Reference 42). This has been considered
due to inadequate doses chosen for the treatment of GERD. Recent trials comparing ran-
itidine at higher doses with placebo indicate that there is a significant difference in symp-
tomatic reliefand healing oferosive esophagitis with two high doses ofranitidine (150 mg
qid and 300 mg qid, respectively) compared to placebo over 12 weeks with the highest
healing gain of 35 percent and 37 percent in one study [43], and 41 percent and 34 per-
cent ateight weeks in another [44]. These data suggest that healing ofesophagitis requires
more effective suppression ofacid secretion since increasing doses ofranitidine from 300
mg bid to 300 mg six times a day correlates dose-dependently with the reduction in the
number and the duration of reflux episodes in GERD [45].
Table 1. Correlation between severity ofsymptoms and acid exposure time.
Acid exposure Reflux symptoms
Groups (no.) time (percent)* (2grade 2)
Normal controls (50) 1:1 0
Patients with no esophagitis (127) 3.4t 63/127 (50%)
Patients with esophagitis (63) 10.6t 42/63 (67%)
Data from Joelsson and Johnsson [21].
*Percent of 24-hr recording.
tSignificant difference vs. controls.
Table 2. Predictive model of mucosal damage and endoscopic grades ofesophagitis.
Grade 1 Grade 2 Grade 3 Grade 4
AUC* (min x mmol/L) 67.1 + 19 142.6 + 38 473.5 + 76 868.1 + 170
Table modified with permission from Barrientos et al. [41].
*p < .001 between grades.
162Huang and Hunt: pH, healing and symptoms
The PPIs have been studied in many well-designed clinical trials, which show a con-
sistent and significantly better effect than H2RA for healing esophagitis and relieving
symptoms (forreviews, see References 42, 46 and 47). In two comprehensive meta-analy-
ses, Chiba et al. combined data from forty-three randomized, endoscopically controlled
studies involving 3710 patients with esophagitis of grades II-IV [48, 49]. The results
showed that omeprazole is significantly more effective both inrelieving the symptoms and
in healing esophagitis [48, 49]. Furthermore, the healing-time curve shows that a signifi-
cantly greater proportion ofpatients were healed with omeprazole at two and four weeks
than H2RAs at eight to 12 weeks [46]. This is also seen with lansoprazole studies in a
more recent review and update ofthe previous meta-analysis [46]. Although there are few
published studies available regarding the effect ofpantoprazole [50], arecentdouble-blind
multicenter study showed that pantoprazole has a similar effect to omeprazole in the treat-
ment of GERD [51]. Moreover, PPIs have been used successfully to heal patients refrac-
tory to standard or even high doses of H2RA [52-55]. The more effective healing of
esophagitis achieved with the PPIs is related directly to the greater degree and the longer
duration ofacid suppression. Omeprazole 20mg/day reduced 24-hrintragastric acidity by
95 percent, while ranitidine 150 mg bid, having a weak effect on food-stimulated gastric
acid secretion during the day, reduced 24-hr intragastric acidity by only 55 percent [56].
Furthermore, the higher dose of omeprazole 40 mg almost completely eliminates acid
reflux episodes in patients ofGERD [57].
In a simple meta-analysis of the published trials of the PPIs in esophagitis of grades
II-IV, healing at four weeks correlates with the various doses ofthe PPIs. Thirty mg lan-
soprazole healed 79 percent ofpatients with esophagitis, while 71 percent, 69 percent and
66 percent ofpatients were healed by 20 mg omeprazole, 40 mg pantoprazole and 15 mg
lansoprazole, respectively. However, 40 mg omeprazole healed 76 percent of patients, a





79 Pantoprazole 15mg 76 [1111111 ~8 studies
00-4% ~~~~~~~~~~~9 71 1111 Ac ......66. meprazole2omg
I'D O lib S A nmeprazole 40mg (D 9~~~~~~~~~~ 9studies
o : | Lansoprazole 30mg
0n
0 n=1 n=-AOR n=1 477 .'
Figure 1. Dosecomparisons and healing rates atfour weeks withvarious PPIs inpatients with
esophagitis grades II-IV.
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reflect the inhibition of 24-hr acid secretion achieved by different doses of the PPIs [57,
58, 59].
A dynamic relationship between the duration ofintragastric pH above 4 and healing
of esophagitis has been shown in our previous study [9]. Treatments that maintain intra-
oesophageal pH above 4 for 96 percent or more ofthe 24-hr period normalize the time of
esophageal exposure to acid and are associated with the highest healing rates [9, 46].
Eight-week healing of esophagitis correlates inversely with esophageal acid exposure.
Thus, the healing rate of esophagitis can be predicted by the duration of suppression of
intragastric acidity above pH 4 which is achieved by any antisecretory drugs [9].
ACID CONTROL FOR SYMPTOM RELIEF AND HEALING IN DU
Acidprofile
Patients with DU generally secrete more gastric acid than normal subjects both at
night and during the day [60, 61]. Historically, studies indicated that basal and maximal
acid output in DU patients was about twice normal, especially in male patients [62].
However, more recent reviews show that there is a considerable overlap between DU
patients and controls [63, 64], and the considerable variation between individuals implies
that 24-hr intragastric pH measurements are not capable of identifying predictably indi-
viduals at risk ofdeveloping DU [46].
Acid, duodenal ulcer andpain
The pathogenesis of ulcer pain is not well understood and has been poorly investi-
gated. Three main factors have been discussed: acid, motility and inflammatory reaction
surrounding the ulcer [65]. Gastric acid is still considered to play a major role in the cau-
sation ofmucosal injury in DU patients. The lack of DU in achlorhydric patients and the
severe peptic ulceration seen in patients with Zollinger-Ellison syndrome also support the
importance of acid in the development of an ulcer. A low intragastric and intraduodenal
pH correlates significantly with epigastric pain in DU patients [66]. More convincing evi-
dence for the role of acid in DU pain comes from a controlled double-blind study that
demonstrated that, in contrast to controls, typical DU pain can be reproduced by direct
acidification of an ulcer crater with hydrochloric acid [67]. The development of acid-
induced pain was seen more commonly in patients with symptoms. Furthermore, the
administration of an anticholinergic agent did not prevent pain, suggesting a mechanism
other than muscular spasm in this group of patients [68]. However, DU pain cannot be
explained entirely by the effect ofacid on the ulcer crater alone, since a contrasting report
regarding the relationship between intraduodenal pH and DU found no significant differ-
ence in gastric and duodenal bulb acidity between hypersecretory DU patients and nor-
mosecretory controls [69]. Thus, other factors must contribute to the ulcer pain, such as
erosive duodenitis or dysmotility of the duodenum and pylorus in some patients [66, 70].
RATIONALE OF ACID SUPPRESSION IN THE MANAGEMENT OF DU
Treatment of DU has been focused on suppressing the secretion of gastric acid. This
has been achieved traditionally by surgery [71], radiotherapy [72] and a spectrum ofphar-
macological agents [73]. Elective surgery has declined dramatically since the introduction
ofeffective drugs ofthe H2RA class in 1970s, and more recently the H+/K+-ATPase PPIs
[73].
Patients with an active DU generally secrete more acid during the 24-hr period than
controls [60, 61]. Nocturnal acid secretion has been considered an important pathophysio-
logical factor in the development ofDU [74] and is a major component ofbasal acid secre-
tion, a target time for pharmacological control by the H2RAs [75]. H2RAs predominantly
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lower basal acid secretion rather than meal-stimulated acid secretion and, thus, have been
targeted at bedtime dosing for healing DU to optimize the effect on the longer period of
basal acid secretion. Several clinical trials have shown that the inhibition ofnocturnal acid
secretion obtained by large single bedtime doses ofH2RAs yield healing rates ofDU com-
parable to or better than those achieved with dose regimens that are aimed at suppressing
acid secretion over the 24-hrperiod [75-78].
Two models of the relationship between ulcer healing and acid suppression by dif-
ferent regimens of antisecretory drugs have been established by our group [8, 79].
Suppression of24-hr intragastric acidity by H2RAs correlates significantly with DU heal-
ing at four weeks. Reduction of nocturnal acidity is primarily responsible for the signifi-
cant correlation [79]. However, when all drug classes studied including omeprazole were
used foranalysis, amoresignificant correlation is shown between the suppression ofover-
all 24-hr acidity and healing rates at four weeks. Thus, suppression ofnocturnal acidity is
increased from 30 percent to about 95 percent by H2RA, and a therapeutic gain of some
20 percent DU healing can be expected at four weeks. However, when suppression of
overall 24-hr acidity is increased from 40 percent to almost 100 percent by inclusion of
the PPI effect, the therapeutic gain is almost doubled to 40 percent [79]. Thus, inhibition
of 24-hr acid secretion is more important than suppression of nocturnal acid secretion
alone in determining DU healing. In contrast to H2RAs, the PPIs provide a significantly
greater degree and longer duration of inhibition ofacid secretion regardless ofthe stimu-
lus. However, it is important to emphasize that the duration of treatment is also a critical
determinant, and the healing rate achieved by omeprazole 20 mg at four weeks can be
approached by H2RAs if the treatment is extended to eight weeks [79].
Further analyses identified the three key parameters determining healing of DU by
antisecretory drugs: the degree ofsuppression ofacid secretion, the duration ofacid sup-
pression over the 24-hr period and the length oftherapy in weeks [8]. Thus, ifintragastric
pH can be maintained above 3 for a period of 18 to 20 hours per day, a 100 percent heal-
ing rate of DU can be predicted at four weeks [8]. This probably explains why the PPIs
heal DU moreeffectively than H2RAs, since 24-hrintragastric acidity studies indicate that
a longer duration and greaterdegree ofacid suppression is achieved by the PPIs, omepra-
zole [80], lansoprazole [58] and pantoprazole [59] when compared to H2RA.
CLINICAL TRIALS IN DUODENAL ULCER
Several well-designed, controlled clinical trials have demonstrated the superiority of
PPIs overH2RAs in the treatment ofduodenal ulcer, and these studies have been analyzed
recently by different reviewers [8, 50, 64, 79, 81-83]. In a meta-analysis, Erikkson et al.
show a significant difference in healing of DU between omeprazole 20 mg o.d. and the
H2RAs ranitidine and cimetidine, at regular doses [82]. A total of3,504 DU patients from
16 double-blind clinical studies were included for analysis. On an intention-to-treat basis,
omeprazole 20 mg o.d. healed 61.7 percent and 87.4 percent DU patients at two and four
weeks, while ranitidine 150 mg b.i.d. or 300 mg h.s. healed 46.5 percent and 76.5 percent
at two and fourweeks, respectively (both p < .001). When omeprazole was compared with
cimetidine 400 or 600 mg b.i.d. or 800 mg h.s., the differences were similar. Another two
meta-analyses revealed the similar healing differences between H2RA and the newer PPIs
lansoprazole 30 mg o.d. [83] and pantoprazole 40 mg o.d. [50], confirming that faster
healing is a characteristic of PPIs in the treatment of DU. Furthermore, a more compre-
hensive meta-analysis pooled data from 279 randomized, double-blind, endoscopically
controlled clinical trials involving 44,870 patients, comparing healing rates ofDU by dif-
ferent drug classes [84]. Among six different drug classes, the PPIs, represented in this
analysis by omeprazole, gave the highest overall healing rate at 80.8 percent, irrespective
of treatment duration. The speed ofhealing calculated as the average slope ofthe healing
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time curve was 22.3 percent ulcers healed per week. However, all classes of drugs have
the potential to approach 100 percent healing if the length of treatment is continued for
long enough [85].
In addition to effective healing of DU, PPIs also provide faster relief of symptoms
than H2RAs [50, 82, 86, 87]. One recent meta-analysis reported that in 1,948 patients,
almost 60 percent patients were symptom free after two weeks treatment with H2RAs,
while in 1,921 patients treated with omeprazole, over 70 percent patients were free ofepi-
gastric pain [82]. Our unpublished analysis shows that 91 percent DU patients were symp-
tomatic at entry to clinical trials. After treatment with omeprazole, the proportion of
patients with symptoms dramatically declined to 31 percent at two weeks and 20 percent
at four weeks. A similar effect on symptom relief was seen with H2RA and antacids ifthe
duration ofthe treatment was long enough (seeTable 3). Ofparticular interest is the obser-
vation that some 20 percent ofDU patients still complain ofsymptoms at the end oftreat-
ment even when almost all (over 95 percent) ulcers are healed by omeprazole [8, 84].
Comparative healing studies with PPIs indicate that lansoprazole 30 mg/day may be
more effective than omeprazole 20 mg/day in healing duodenal ulcer as reflected by a
greater proportion ofulcer healed at an earlier time point [81, 88]. In a recent review, two
of three comparative studies showed that, at recommended doses, lansoprazole 30 mg
healed significantly more proportion of DU patients than omeprazole 20 mg after two
weeks (a therapeutic gain of 16 and 19 percent, respectively). However, there was no sig-
nificant difference between these two PPIs after four weeks [81]. Pantoprazole 40 mg/day
did not show much difference from omeprazole 20 mg/day in healing DU and relief of
symptoms [89, 90]. The difference in DU healing seen between lansoprazole and omepra-
zole may be due to a more rapid onset of the antisecretory effect of lansoprazole 30 mg
since the oral bioavailability of lansoprazole is higher than that of omeprazole [91]. In
addition, 30 mg/day lansoprazole is more effective in increasing intragastric pH above 3
for the 24-hr period than omeprazole 20 mg/day [58]. When compared to H2RAs, both
lansoprazole and pantoprazole are significantly more effective than H2RA in healing DU
and reliefofsymptoms [50, 86, 87]. The higher proportion ofsymptom-free patients seen
with PPI treatment could be explained by the greater and more prolonged suppression of
acid secretion over the 24-hr period achieved by PPI as compared to H2RA [9, 58].
IMPORTANCE OF H. PYLORI ERADICATION IN DU HEALING
With the recent appreciation of the role ofH. pylori infection in the pathogenesis of
duodenal ulcer, many clinical trials have been carried out to heal duodenal ulcer with anti-
secretory drugs and simultaneously to cure the infection withantimicrobials [92-94]. Thus,
the combination of antimicrobials with antisecretory drugs might be expected to acceler-
ate DU healing. In a randomized, controlled study, Graham et al. compared the effect of
ranitidine plus tetracycline, metronidazole and bismuth subsalicylate, withranitidine alone
Table 3. Percentage ofDU patients with symptoms over time by drug classes.
Drug (arms) Entry (%) 2 weeks (%) 4 weeks (%) 6 weeks (%) 8 weeks (%)
Placebo (29) 340/366* (93) 318/460 (69) 523/914 (57) 37/72 (51) 11/22 (52)
Omeprazole (13) 683/754 (91) 333/1075 (31) 118/597 (20)
H2RA (110) 2373/2816 (84) 1599/4133 (39) 1196/5553 (22) 195/1176 (17) 68/375 (18)
Antacids (12) 114/162 (70) 93/204 (46) 75/338 (22) 6/30 (20) 9/40 (23)
Table modified with permission from Morgan et al., unpublished data
*Number with symptoms/number evaluated
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on DU healing [95]. The results showed that DU healing was morerapid in patients receiv-
ing ranitidine plus triple therapy than in those given ranitidine alone. Lifetable analysis
demonstrated a leftward shift ofthe healing curve. More recently, PPIs combined with one
or more antimicrobials have been accepted increasingly as effective, safe and simple regi-
mens to heal H. pylori positive DU patients, to cure the infection and to prevent ulcer
recurrence [96-98]. Omeprazole plus clarithromycin dual therapy healed 98 percent ofDU
patients at four weeks [96, 97]. When metronidazole was added, 100 percent of patients
were healed [98]. These healing rates are superior to the use ofeither omeprazole (94 per-
cent) [96, 97] or clarithromycin alone (71 percent) [96]. The accelerated healing environ-
ment achieved by combined therapy may result from a synergistic effect between antise-
cretory drugs and antimicrobials since PPIs such as omeprazole or lansoprazole reduce
intragastric acidity, which allows acid-labile antibiotics to work more effectively [99].
Moreover, eradication of H. pylori results in normalization of acid secretion [5, 100-102]
and pepsin output [101] although it takes time to return, and the reduction of acid secre-
tion and pepsin output may eventually reduce the risk of ulcer recurrence.
Data on the effect of antisecretory and antimicrobial drug combination therapy on
symptom relief in DU patients are scant. Many regimens, perse, especially bismuth triple
therapy, have poor tolerability and cause symptoms themselves [103]. Compliance has a
significant influence on the success rate of treatment [103]. Since the PPIs are the best
agents forrapid ulcer healing and fastreliefofsymptoms, dual ortriple antimicrobial ther-
apy including a PPI is a logical choice for ulcer healing and resolution ofsymptoms in H.
pylori-positive DU patients.
Influence ofotherfactors on DU healing
Smoking, ulcer size, and prior ulcer history have generally been considered as risk
factors delaying duodenal ulcer healing [104-106]. The presence of these risk factors
affect length ofantisecretory treatment and healing ofduodenal ulcer [105]. In a prospec-
tive multicenter study, Armstrong et al. showed that the speed of DU healing correlates
closely with a number of risk factors [105]. In the absence of risk factors, the mean DU
healing time achieved with ranitidine 300 mg daily was 3.3 weeks, rising to 3.7 weeks for
one, 4.4 weeks for two, and 5.1 weeks for three to five risk factors [105]. The effect of
these risk factors is cumulative. At four weeks, 82.7 percent of patients with none of the
risk factors were healed, whereas healing rates decreased to 50 percent from 64.9 percent
in patients with two more risk factors. Thus, patients with additional risk factors require a
longer period ofantisecretory treatment with H2RA to achieve ulcer healing. It is notclear
whether smoking affects acid secretion [107]. However, in animal studies, smoking aggra-
vates acetic acid-induced peptic ulcers [107-108]. Furthermore, PPIs such as omeprazole
and lansoprazole have been shown more effective than H2RA in healing duodenal ulcer in
smokers [86, 109]. Thus, acid suppression has an important implications in the treatment
of peptic ulcers in smokers.
ACID CONTROL FOR SYMPTOM RELIEF AND HEALING IN GU
Rationale ofAcid Suppression in the Management ofGU
Most GU patients are normosecretors or hyposecretors as determined by basal or
stimulated gastric acid secretion compared to controls [13, 110]. Twenty-four-hour intra-
gastric pH measurements show that the median integrated acidity in GU patients is lower
than healthy subjects [13]. Nevertheless, gastric acid is still necessary for the formation of
a gastric ulcer. Ifthe mucosal integrity is impaired, as in gastritis, acid back diffusion may
occur, disrupting the mucosa and predisposing to ulceration even with normal or low lev-
els of acidity. As with DU, the mechanism of GU pain is not clear. It seems that gastric
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mucosal inflammation may be more relevant than gastric acid in pain development since
symptomatic GU patients may be hypochlorhydric [111].
Despite these observations, suppression of gastric acid secretion has remained the
mainstay oftreatment for gastric ulcer, although the relationship between acid suppression
and gastric ulcer healing is not as clear-cut as for DU [112]. The results of a meta-analy-
sis from our group reported that the primary variables determining the healing of gastric
ulcer are similar to those for duodenal ulcer although the duration of treatment is the most
important determinant [10]. Suppression of 24-hr intragastric acidity also correlates sig-
nificantly with GU healing; however, the therapeutic gain from increasing the suppression
of acidity is not as relevant as for DU [113]. In contrast to H2RA, the PPI regimens, such
as omeprazole 20 mg to 40 mg o.d., which have the greatest effect on 24-hr intragastric
acidity, provide the highest healing rates at two, four and eight weeks [113]. However, the
difference between these two drug classes tends to become smaller as the duration oftreat-
ment extends from two weeks to eight weeks. If intragastric pH can be maintained at or
above 3 for 18 to 20 hr of the day, almost 100 percent of gastric ulcer can be predicted to
heal at eight weeks, while this can be achieved at four weeks for duodenal ulcer [8]. This
is in accordance with clinical observations that gastric ulcers take a longer time to heal
than duodenal ulcers and that persistence with effective treatment is an important factor to
ensure complete ulcer healing [8, 10].
Clinical Trials in GU
In comparative studies, PPIs have produced consistently higher rates of GU healing
over H2RAs [114-118]. A meta-analysis of trialscomparing the effect of omeprazole 20
mg o.d. with ranitidine 150 mg b.i.d or 300 mg h.s. on healing of GU showed a therapeu-
tic gain of9.9 at 4 weeks (p = .005) and 6.7 at 8 weeks (p = .02) for omeprazole over ran-
itidine [82]. Similarly, pooled results of two studies indicates a significant difference in
ulcer healing between pantoprazole 40 mg o.d. and ranitidine 300 mg h.s. at four and eight
weeks yielding a therapeutic gain of32 percent and 15 percent respectively (both p < .001)
[50]. Lansoprazole 30 mg o.d. also showed a superiority ofhealing GU over ranitidine 300
mg h.s. or 150 mg b.i.d. at four and eight weeks [116,117], but on an intention-to-treat
basis, there is no significant difference in healing between lansoprazole and ranitidine at
eight weeks (81 percent vs 76 percent [116], 98.6 percent vs 91.4 percent [117]). In con-
trast to omeprazole, the newer PPIs, pantoprazole 40 mg o.d. and lansoprazole 30 mg o.d.
seem to be more effective than omeprazole 20 mg o.d. at four weeks in healing GU but
results are similar at eight weeks [90, 119]. These clinical observations may reflect the
pharmacodynamic differences between the PPIs since lansopraozole 30 mg o.d. has a
higher oral bioavailability and a more rapid onset of antisecretory effect than omeprazole
[91]. In addition, lansoprazole 30 mg o.d. is more.effective in increasing gastric pH above
3 and maintaining this over a longer duration of the 24-hr period than omeprazole 20 mg
o.d. [58].
PPIs show a less dramatic effect on symptoms and are only marginally better than
ranitidine in relieving symptoms in patients with gastric ulcer [82, 116-118]. One meta-
analysis shows that 65.3 percent of patients treated with omeprazole 20 mg o.d. were
symptom-free at 2 weeks compared to 56.4 percent of patients treated with ranitidine 150
mg. b.i.d. or 300 mg h.s. (p < .05) [82]. The resolution of day-time pain contributes main-
ly to this difference because there is no significant difference in relieving nocturnal pain
between the groups [82]. In contrast to ranitidine 300 mg h.s. or 150 mg b.i.d., initial stud-
ies with pantoprazole 40 mg o.d. or lansoprazole 30 mg o.d. have not shown any signifi-
cant differences in improving GU symptoms [116-118]. These clinical observations could
suggest that, as with healing of gastric ulcer, the length of treatment with antisecretory
agents is the major factor determining the relief of GU symptoms.
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The association between H. pylori infection and gastric ulcer is less clear than with
duodenal ulcer. It is not clear whether H. pylori infection affects acid secretion in GU
patients. However, eradication of H. pylori infection still has important implications for
the treatment of gastric ulcer. Clinical trials have not shown that antimicrobials increase
the speed ofGU healing achieved by antisecretory agents alone, but eradication treatment
dramatically reduces the recurrence rate of gastric ulcer in the same way as is seen with
duodenal ulcer [120-122].
Smoking and ulcer size are also risk factors for slow healing of gastric ulcer [104].
However, concomitant use ofa non-steroidal anti-inflammatory drug is more closely relat-
ed with slowed GU healing than with DU [103]. Gastric ulcers heal faster if the drug is
stopped [123].
CONCLUSIONS
Gastric acid secretion is important for maintaining normal gastrointestinal function.
Suppression of gastric acid secretion has proved very effective in the treatment of acid-
related disorders and remains the major form of treatment. Three key parameters deter-
mine the effect of treatment with antisecretory drugs: the degree and the duration of acid
suppression and the length of treatment. The PPIs have been considered the best agents
forhealing esophagitis andpeptic ulcers. Moreover, symptom reliefis well correlated with
the degree of suppression of gastric acid secretion in patients with GERD but correlates
less well for symptom reliefofDU and GU. The combination ofantimicrobials with anti-
secretory drugs appears to accelerate the healing ofduodenal ulcer.
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